Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the discussed pages of the transcript. The company highlights a strong balance sheet with a low gearing ratio (standalone 0.02x, group level 0.11x) and net cash balances, indicating healthy financials without a present need for additional debt. Focus is on operational and new capex funding internally, with expected operational capex of INR 16-20 crores in FY24, and INR 5-7 crores towards new SOCE units. No references were made to plans for raising funds through equity or debt in the near future during t

Any current/future capex/capital investment/strategic investment?

Q1 FY24 operational capex was about INR 4 crores, split evenly between replacement and new capex. Expected operational capex for FY24 is between INR 16-20 crores. New capex includes INR 5-7 crores towards operationalizing one SOCE unit under the FOSO model. Capex planned for operationalizing new hospitals, specifically Nashik hospital expected in late FY23 or early FY24. Mumbai hospital project is planned for the next 3-4 years but still awaiting site visit approvals from the Joint Commission and BMC. Investment in building capabilities in other specialties alongside marketing spend increased

Future growth expectations in sales/revenue/volumes?

Hospital business EBITDA margin is expected to expand in coming quarters due to anticipated revenue growth. SOCE franchisee vertical aims to establish over 50 franchise hospitals across India within 3-4 years, with surgery count and revenue growing ~40% YoY this quarter. Implant business targets 50%+ revenue growth in FY24, backed by new product launches and market expansions in U.S., India, Southeast Asia, Latin America, and Indonesia. Shalby Advanced Technologies (SAT) aims for mid-single-digit EBITDA margin profitability in FY24 and $100 million revenue in 5 years. Home Care segment

Future growth expectations in earnings/operating earnings/profits/EPS?

Hospital business expected to sustain double-digit growth in inpatient and surgery counts, with occupancy rates improving to 50% in Q1 FY '24 and likely to ramp up further. EBITDA margin of 23% in hospital operations expected to expand in coming quarters due to higher revenue and investments in new specialties. Implant business aims for 50%+ revenue growth in FY '24, targeting $18 million full-year revenue with new product launches and market expansion, including $0.35-$0.5 million expected sales from Indonesia. SOCE franchisee units to grow from 4 to 8-9 operational units by end of FY '24,

Current/ Expected Orderbook/ Pending Orders?

The order from Indonesia is around $350,000 to $0.5 million expected to be completed this year, with the first order at about $100,000+. Some orders from Argentina and Paraguay have been delayed due to regulatory approval delays. There is no explicit detailed mention of a total current or expected order book value in the transcript. The implant business plans to grow 50%+ over last year with a full-year target of $18 million revenue. The Ambition Knee, a major product launch expected to be a game changer in India and Southeast Asia, was delayed due to instrument manufacturing issues but is exp

Shalby LtdQ2 FY24

Shalby Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹154P/E: 46.9Market Cap: ₹1.8K Cr

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Hospital business EBITDA margin is expected to expand in coming quarters due to anticipated revenue growth.
→SOCE franchisee vertical aims to establish over 50 franchise hospitals across India within 3-4 years, with surgery count and revenue growing ~40% YoY this quarter.
→Implant business targets 50%+ revenue growth in FY24, backed by new product launches and market expansions in U.S., India, Southeast Asia, Latin America, and Indonesia.
→Shalby Advanced Technologies (SAT) aims for mid-single-digit EBITDA margin profitability in FY24 and $100 million revenue in 5 years.
→Home Care segment expects to grow from current 1.5-2% to 5% of hospital top line over 2-3 years.
→Hospital occupancy and surgery counts are rising, with hospital occupancy at 50% and surgery growth at 14% YoY.
→ARPOB levels sustained due to favorable specialty mix and insurance renegotiations, supporting revenue growth.

Margin guidance

Category 3

→Hospital business expected to sustain double-digit growth in inpatient and surgery counts, with occupancy rates improving to 50% in Q1 FY '24 and likely to ramp up further.
→EBITDA margin of 23% in hospital operations expected to expand in coming quarters due to higher revenue and investments in new specialties.
→Implant business aims for 50%+ revenue growth in FY '24, targeting $18 million full-year revenue with new product launches and market expansion, including $0.35-$0.5 million expected sales from Indonesia.
→SOCE franchisee units to grow from 4 to 8-9 operational units by end of FY '24, with surgeries and revenue growing 40%+ YoY.
→Home Care segment is growing rapidly (71% revenue growth Q1 YoY) and expected to contribute up to 5% of hospital topline in 2-3 years.
→Overall, positive outlook with EBITDA and profits expected to improve driven by operational efficiencies, new capex, and expanded geographic presence.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or future fundraising through debt or equity in the discussed pages of the transcript.
→The company highlights a strong balance sheet with a low gearing ratio (standalone 0.02x, group level 0.11x) and net cash balances, indicating healthy financials without a present need for additional debt.
→Focus is on operational and new capex funding internally, with expected operational capex of INR 16-20 crores in FY24, and INR 5-7 crores towards new SOCE units.
→No references were made to plans for raising funds through equity or debt in the near future during the Q1 FY24 earnings call segments covered.

Order book

→The order from Indonesia is around $350,000 to $0.5 million expected to be completed this year, with the first order at about $100,000+.
→Some orders from Argentina and Paraguay have been delayed due to regulatory approval delays.
→There is no explicit detailed mention of a total current or expected order book value in the transcript.
→The implant business plans to grow 50%+ over last year with a full-year target of $18 million revenue.
→The Ambition Knee, a major product launch expected to be a game changer in India and Southeast Asia, was delayed due to instrument manufacturing issues but is expected to launch in the coming months, which will likely boost future orders.
→Overall, the company is confident about growth and new markets for its implant business and expects stronger sales in the second half of the year.

Capex plans

Yes

→Q1 FY24 operational capex was about INR 4 crores, split evenly between replacement and new capex.
→Expected operational capex for FY24 is between INR 16-20 crores.
→New capex includes INR 5-7 crores towards operationalizing one SOCE unit under the FOSO model.
→Capex planned for operationalizing new hospitals, specifically Nashik hospital expected in late FY23 or early FY24.
→Mumbai hospital project is planned for the next 3-4 years but still awaiting site visit approvals from the Joint Commission and BMC.
→Investment in building capabilities in other specialties alongside marketing spend increased by 100 bps compared to last year.
→Strategic investments include expanding SOCE franchise hospitals with plans to reach over 50 units in 3-4 years.
→Continuous investment in sales, engineering, and supply chain to drive growth and improve efficiencies, especially for the implant business.

How does Shalby Ltd rank vs peers in ?

Pro feature

1Shalby Ltd

Rev 2Mar 3

See full sector rankings

Want more stocks like Shalby Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio